Rapport Therapeutics, Inc. (RAPP)
RAPPNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$25.96
-0.1100 (-0.42%) today
At the close, Nov 10, 4:00 PM ET. After hours $25.66 -1.17%
- Market cap
- $1.54bn
- P/E
- –
- EPS, last 4 quarters
- $-3.17
- Dividend yield
- –
- Day range
- $25.30 to $26.90
- 52-week range
- $22.06 to $52.93
- Average volume
- 858.3k
- Previous close
- $26.07
Analysts
14 coveringBuy14 buy, 0 hold, 0 sell
Targets a year out average $68.00, +161.9% from here
Earnings
next estimate $-0.8700Next report
Dec 2025
-10.8%
Mar 2026
+25.0%
Jun 2026
-28.0%
Sep 2026
+30.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | $20.00m | – | – |
| Gross profit | – | $20.00m | – | – |
| Operating income | -$38.51m | -$24.21m | -$60.81m | -$44.09m |
| Net income | -$33.76m | -$19.86m | -$56.62m | -$40.23m |
News
8 latest- Rapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock Down RTTNews · Oct 28, 2026
- Rapport Therapeutics Launches $350 Mln Stock And Convertible Notes Offerings; Stock Down RTTNews · Oct 28, 2026
- Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania TrialMarketBeat · Oct 25, 2026
- Rapport Therapeutics Consensus Price Target Increased by 10.79% to $69.65Fintel · Oct 23, 2026
- Thursday 10/22 Insider Buying Report: FBK, RAPPBNK Invest · Oct 22, 2026
- Rapport Therapeutics Enters Oversold Territory (RAPP)BNK Invest · Oct 21, 2026
- Rapport's RAP-219 Meets Both Endpoints In Phase 2 Bipolar Mania Trial; Stock Surge 30% In Premarket RTTNews · Oct 20, 2026
- UBS Initiates Coverage of Rapport Therapeutics at BuyFintel · Oct 16, 2026
The company
is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company's founders made pioneering discoveries related to the function of receptor associated proteins ('RAPs') in the brain, which form the basis of Rapport's RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The Company's late-stage programs include RAP-219 in epilepsy, including focal onset seizures and primary generalized tonic-clonic seizures, and in bipolar mania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- rapportrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.